A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival (PFS) in second-line metastatic breast cancer. But ...
By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...
Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the ...
Pfizer has entered into a global collaboration and license agreement with YaoPharma for the development, manufacturing and commercialization of YP05002, a small-molecule GLP-1 receptor agonist ...
Pfizer has claimed its first regulatory approval for a GLP-1 agonist in obesity, getting a green light in China for ...
The stock is down, but the good news is that it sports a fat dividend yield of 6.4%. Pfizer has been struggling lately, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results